Albany, NewYork (PRWEB) December 14, 2013
GBI Research has released the pharma report - “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract.
Click here to download full report with TOC at http://www.researchmoz.us/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-report.html.
They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.
A brief introduction to the two indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment algorithms.
In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses.
A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
Browse all GBI Market Research Report at http://www.researchmoz.us/publisher/gbi-research-2.html.
Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Reasons to Buy
Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
All latest market research report at http://www.researchmoz.us/latest-report.html.
Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers.
Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers.
Equine Healthcare Market
The global equestrian market (http://www.researchmoz.us/equine-healthcare-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019-report.html) is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets; the equine healthcare market ranks as the one of the key secondary markets. This report exclusively studies the market for equine healthcare from varied aspects such as, in terms of equine diagnostic products, equine therapeutic products and equine supplement products; and is thus classified into three prime segments namelyequine diagnostic products market, equine therapeutic products market and equine supplement products market.
Global and China Insulin Industry Report, 2013 - 2017
As the third largest human health disease (http://www.researchmoz.us/global-and-china-insulin-industry-report-2013-2017-report.html) following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size. In 2012 the global insulin market size reached US$20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948